Moderna Inc. (NASDAQ:MRNA) dosed the first participants in a Phase I/II trial of quadrivalent seasonal mRNA influenza vaccine mRNA-1010 that will help determine whether the manufacturing and efficacy
AI company Genesis raises $52M series AStanford University spinout Genesis Therapeutics Inc. raised $52 million in a series A round led by Rock Springs Capital; T. Rowe Price Associates, Andreessen